SCHEMBL452380

SCHEMBL452380

CCCC[n+]1ccccc1C1=C2C=CC(=N2)C(c2cccc[n+]2CCCC)=C2C=CC(=N2)C(c2cccc[n+]2CCCC)=C2C=CC(=N2)C(c2cccc[n+]2CCCC)=C2C=CC1=N2

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 7/20 0.37
▸ RAB9A P51151 6/20 0.37
▸ SMN1; SMN2 Q16637 6/20 0.37
▸ KDM4E B2RXH2 5/20 0.37
▸ HTT P42858 5/20 0.37
▸ MEN1 O00255 5/20 0.37
▸ KMT2A Q03164 5/20 0.37
▸ NPSR1 Q6W5P4 3/20 0.37
▸ LMNA P02545 2/20 0.37
▸ MAPK1 P28482 2/20 0.37
▸ RAD52 P43351 2/20 0.37
▸ RGS12 O14924 1/20 0.37
▸ USP2 O75604 1/20 0.37
▸ HSP90AA1 P07900 1/20 0.37
▸ THRB P10828 1/20 0.37
▸ MCL1 Q07820 1/20 0.37
▸ POLB P06746 1/20 0.36
▸ ALDH1A1 P00352 4/20 0.34
▸ GAA P10253 4/20 0.34
▸ GLA P06280 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL449177 0.94 SMN1; SMN2 (0.44) NPC1RAB9ASMN1; SMN2KDM4EHTT
SCHEMBL448360 0.94 SMN1; SMN2 (0.44) NPC1RAB9ASMN1; SMN2KDM4EHTT
SCHEMBL452206 0.94 SMN1; SMN2 (0.44) NPC1RAB9ASMN1; SMN2KDM4EHTT
SCHEMBL452117 0.94 SMN1; SMN2 (0.44) NPC1RAB9ASMN1; SMN2KDM4EHTT
SCHEMBL450265 0.91 NPC1 (0.31) NPC1RAB9ASMN1; SMN2POLB
SCHEMBL453032 0.86 KDM4E (0.31) NPC1RAB9ASMN1; SMN2KDM4EHTT
SCHEMBL446700 0.84 NPC1 (0.37) NPC1RAB9ASMN1; SMN2KDM4EHTT
SCHEMBL449282 0.84 NPC1 (0.37) NPC1RAB9ASMN1; SMN2KDM4EHTT
SCHEMBL447626 0.84 NPC1 (0.37) NPC1RAB9ASMN1; SMN2KDM4EHTT
SCHEMBL3521680 0.83 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120065181-A1 METHOD OF PROVIDING NEUROPROTECTION USING SUBSTITUTED PORPHYRINS DUKE UNIVERSITY 2012-03-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065181-A1 METHOD OF PROVIDING NEUROPROTECTION USING SUBSTITUTED PORPHYRINS SOD1, PYGB, PSAP NPC1 955/4885RAB9A 3499/4885SMN1; SMN2 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback